VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
Mr. Pony LU, CEO of
Lonapegsomatropin is a prodrug of somatropin administered once weekly. By leveraging the innovative technology platform TransConTM (transient conjugation), it is designed to provide sustained release of active, unmodified somatropin, the same growth hormone used in daily pediatric GHD treatments. The unmodified, unbound somatropin released from lonapegsomatropin has the identical 191 amino-acid sequence and size (22 kDa) as endogenous growth hormone.
Lonapegsomatropin and TransCon technology are owned and developed by
Approval No.: COMU2024029/EN/PR
About
VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients' need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases. VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in
For more information, please visit our website:
http://www.visenpharma.com/
Contact us:
info@visenpharma.com
View original content:https://www.prnewswire.com/news-releases/visen-announces-acceptance-of-a-biologics-license-application-for-lonapegsomatropin-in-china-302082740.html
SOURCE